SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 76,808 shares, a growth of 44.8% from the January 15th total of 53,042 shares. Based on an average daily volume of 462,687 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the shares of the stock are short sold. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 462,687 shares, the short-interest ratio is currently 0.2 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Savvy Advisors Inc. bought a new position in SOPHiA GENETICS in the 3rd quarter valued at $48,000. Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS in the third quarter worth $49,000. Perkins Capital Management Inc. bought a new stake in SOPHiA GENETICS during the fourth quarter valued at $49,000. GSA Capital Partners LLP bought a new stake in SOPHiA GENETICS during the third quarter valued at $59,000. Finally, Susquehanna International Group LLP purchased a new position in SOPHiA GENETICS during the third quarter worth about $88,000. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Price Performance

Shares of NASDAQ SOPH opened at $4.74 on Friday. The company has a market capitalization of $320.33 million, a PE ratio of -10.30 and a beta of 1.11. The company has a quick ratio of 2.62, a current ratio of 2.80 and a debt-to-equity ratio of 0.78. The stock’s 50 day moving average price is $4.94 and its 200-day moving average price is $4.31. SOPHiA GENETICS has a twelve month low of $2.58 and a twelve month high of $5.70.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on SOPH shares. Wall Street Zen upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Saturday, November 1st. BTIG Research increased their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Finally, Guggenheim increased their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.